{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:19:43Z","timestamp":1786961983260,"version":"build-2736575974"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41401-026-01756-2","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:24:04Z","timestamp":1772612644000},"page":"1733-1748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Technology-enabled insights into SLC transporters in MAFLD: redefining the multi-hit pathogenesis and therapeutic landscape"],"prefix":"10.1038","volume":"47","author":[{"given":"Joseph","family":"Tawai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"1756_CR1","first-page":"724","volume":"22","author":"H Chen","year":"2024","unstructured":"Chen H, Zhou Y, Hao H, Xiong J. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies. Chin J Nat Med. 2024;22:724\u201345.","journal-title":"Chin J Nat Med"},{"key":"1756_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01721-4","volume":"7","author":"SP Cartland","year":"2017","unstructured":"Cartland SP, Harith HH, Genner SW, Dang L, Cogger VC, Vellozzi M, et al. Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice. Sci Rep. 2017;7:1898.","journal-title":"Sci Rep"},{"key":"1756_CR3","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","volume":"119","author":"C Grander","year":"2023","unstructured":"Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119:1787\u201398.","journal-title":"Cardiovasc Res"},{"key":"1756_CR4","doi-asserted-by":"crossref","unstructured":"Carnagarin R, Tan K, Adams L, Matthews VB, Kiuchi MG, Marisol Lugo Gavidia L, et al. Metabolic-dysfunction-associated fatty liver disease (MAFLD) is a condition associated with heightened sympathetic activation. Int J Mol Sci. 2021;22:4241.","DOI":"10.3390\/ijms22084241"},{"key":"1756_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101271","volume":"7","author":"G Feng","year":"2025","unstructured":"Feng G, Targher G, Byrne CD, Yilmaz Y, Wai-Sun Wong V, Adithya Lesmana CR, et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2025;7:101271.","journal-title":"JHEP Rep"},{"key":"1756_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1502263","volume":"15","author":"H Fan","year":"2024","unstructured":"Fan H, Wang R, Wen B, Xiong J. Biomarkers and potential therapeutic targets driving progression of non-alcoholic steatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis. Front Immunol. 2024;15:1502263.","journal-title":"Front Immunol"},{"key":"1756_CR7","doi-asserted-by":"publisher","first-page":"115028","DOI":"10.1016\/j.biopha.2023.115028","volume":"165","author":"Q Xu","year":"2023","unstructured":"Xu Q, Feng M, Ren Y, Liu X, Gao H, Li Z, et al. From NAFLD to HCC: advances in noninvasive diagnosis. Biomed Pharmacother. 2023;165:115028.","journal-title":"Biomed Pharmacother"},{"key":"1756_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","volume":"8","author":"WP Esler","year":"2019","unstructured":"Esler WP, Bence KK. Metabolic targets in nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol. 2019;8:247\u201367.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1756_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116723","volume":"277","author":"R Amorim","year":"2024","unstructured":"Amorim R, Soares P, Chavarria D, Benfeito S, Cagide F, Teixeira J, et al. Decreasing the burden of non-alcoholic fatty liver disease: from therapeutic targets to drug discovery opportunities. Eur J Med Chem. 2024;277:116723.","journal-title":"Eur J Med Chem"},{"key":"1756_CR10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.tips.2024.08.009","volume":"45","author":"NF Brisnovali","year":"2024","unstructured":"Brisnovali NF, Haney C, Goedeke L. Rezdiffra\u2122 (resmetirom): a THR-\u03b2 agonist for non-alcoholic steatohepatitis. Trends Pharmacol Sci. 2024;45:1081\u20132.","journal-title":"Trends Pharmacol Sci"},{"key":"1756_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509.","journal-title":"N Engl J Med"},{"key":"1756_CR12","first-page":"881","volume":"44","author":"ZQ Tang","year":"2022","unstructured":"Tang ZQ, Shi L, Xiong J. Progress of solute carrier SLC family in nonalcoholic fatty liver disease. Yi Chuan. 2022;44:881\u201398.","journal-title":"Yi Chuan"},{"key":"1756_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1510080","volume":"15","author":"J Du","year":"2024","unstructured":"Du J, Shen M, Chen J, Yan H, Xu Z, Yang X, et al. The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications. Front Pharmacol. 2024;15:1510080.","journal-title":"Front Pharmacol"},{"key":"1756_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jmcb\/mjy052","volume":"11","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhang Y, Sun K, Meng Z, Chen L. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development. J Mol Cell Biol. 2019;11:1\u201313.","journal-title":"J Mol Cell Biol"},{"key":"1756_CR15","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/febs.15531","volume":"288","author":"MD Pizzagalli","year":"2021","unstructured":"Pizzagalli MD, Bensimon A, Superti-Furga G. A guide to plasma membrane solute carrier proteins. FEBS J. 2021;288:2784\u2013835.","journal-title":"FEBS J."},{"key":"1756_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s44320-025-00106-4","volume":"21","author":"T Wiedmer","year":"2025","unstructured":"Wiedmer T, Teoh ST, Christodoulaki E, Wolf G, Tian C, Sedlyarov V, et al. Metabolic mapping of the human solute carrier superfamily. Mol Syst Biol. 2025;21:560\u201398.","journal-title":"Mol Syst Biol"},{"key":"1756_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cmet.2019.11.020","volume":"31","author":"HC Yoo","year":"2020","unstructured":"Yoo HC, Park SJ, Nam M, Kang J, Kim K, Yeo JH, et al. A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab. 2020;31:267\u201383.e12.","journal-title":"Cell Metab"},{"key":"1756_CR18","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.celrep.2018.12.100","volume":"26","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Feng Z, Zhang Y, Sun Y, Chen Y, Liu X, et al. Gain-of-function mutations of SLC16A11 contribute to the pathogenesis of type 2 diabetes. Cell Rep. 2019;26:884\u201392.e4.","journal-title":"Cell Rep"},{"key":"1756_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8208","volume":"6","author":"HHM Draisma","year":"2015","unstructured":"Draisma HHM, Pool R, Kobl M, Jansen R, Petersen AK, Vaarhorst AAM, et al. Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels. Nat Commun. 2015;6:7208.","journal-title":"Nat Commun"},{"key":"1756_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12944-024-02248-0","volume":"23","author":"YJ Park","year":"2024","unstructured":"Park YJ, Moon S, Choi J, Kim J, Kim HJ, Son HY, et al. Genome-wide association study for metabolic syndrome reveals APOA5 single-nucleotide polymorphisms with multilayered effects in Koreans. Lipids Health Dis. 2024;23:272.","journal-title":"Lipids Health Dis"},{"key":"1756_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2025.01.015","volume":"188","author":"A Khan","year":"2025","unstructured":"Khan A, Liu Y, Gad M, Kenny TC, Birsoy K. Solute carriers: the gatekeepers of metabolism. Cell. 2025;188:869\u201384.","journal-title":"Cell"},{"key":"1756_CR22","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00424-020-02411-3","volume":"472","author":"GD Holman","year":"2020","unstructured":"Holman GD. Structure, function and regulation of mammalian glucose transporters of the SLC2 family. Pfl\u00fcgers Arch. 2020;472:1155\u201375.","journal-title":"Pfl\u00fcgers Arch"},{"key":"1756_CR23","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1007\/s11033-023-08535-w","volume":"50","author":"B Sun","year":"2023","unstructured":"Sun B, Chen H, Xue J, Li P, Fu X. The role of GLUT2 in glucose metabolism in multiple organs and tissues. Mol Biol Rep. 2023;50:6963\u201374.","journal-title":"Mol Biol Rep"},{"key":"1756_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1042\/BST20221066","volume":"51","author":"J van Gerwen","year":"2023","unstructured":"van Gerwen J, Shun-Shion AS, Fazakerley DJ. Insulin signalling and GLUT4 trafficking in insulin resistance. Biochem Soc Trans. 2023;51:1057\u201369.","journal-title":"Biochem Soc Trans"},{"key":"1756_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00424-013-1369-y","volume":"466","author":"AM Pajor","year":"2014","unstructured":"Pajor AM. Sodium-coupled dicarboxylate and citrate transporters from the SLC13 family. Pflug Arch. 2014;466:119\u201330.","journal-title":"Pflug Arch"},{"key":"1756_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.mam.2012.12.001","volume":"34","author":"MJ Bergeron","year":"2013","unstructured":"Bergeron MJ, Cl\u00e9men\u00e7on B, Hediger MA, Markovich D. SLC13 family of Na+-coupled di- and tri-carboxylate\/sulfate transporters. Mol Asp Med. 2013;34:299\u2013312.","journal-title":"Mol Asp Med."},{"key":"1756_CR27","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1097\/HEP.0000000000000314","volume":"78","author":"L Cheng","year":"2023","unstructured":"Cheng L, Deepak R, Wang G, Meng Z, Tao L, Xie M, et al. Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPK\u03b1, mediating lipid metabolism and tumorigenesis. Hepatology. 2023;78:1828\u201342.","journal-title":"Hepatology."},{"key":"1756_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-021-04025-w","volume":"599","author":"Y Wang","year":"2021","unstructured":"Wang Y, Yen FS, Zhu XG, Timson RC, Weber R, Xing C, et al. SLC25A39 is necessary for mitochondrial glutathione import in mammalian cells. Nature. 2021;599:136\u201340.","journal-title":"Nature"},{"key":"1756_CR29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s42003-024-07110-8","volume":"7","author":"C Ohanele","year":"2024","unstructured":"Ohanele C, Peoples JN, Karlstaedt A, Geiger JT, Gayle AD, Ghazal N, et al. The mitochondrial citrate carrier SLC25A1 regulates metabolic reprogramming and morphogenesis in the developing heart. Commun Biol. 2024;7:1422.","journal-title":"Commun Biol"},{"key":"1756_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.mam.2012.07.010","volume":"34","author":"CM Anderson","year":"2013","unstructured":"Anderson CM, Stahl A. SLC27 fatty acid transport proteins. Mol Asp Med. 2013;34:516\u201328.","journal-title":"Mol Asp Med"},{"key":"1756_CR31","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/j.gastro.2006.02.006","volume":"130","author":"H Doege","year":"2006","unstructured":"Doege H, Baillie RA, Ortegon AM, Tsang B, Wu Q, Punreddy S, et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology. 2006;130:1245\u201358.","journal-title":"Gastroenterology"},{"key":"1756_CR32","doi-asserted-by":"crossref","unstructured":"Dawson PA. Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol. 2011;201:169\u2013203.","DOI":"10.1007\/978-3-642-14541-4_4"},{"key":"1756_CR33","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/hep.28991","volume":"65","author":"M Trauner","year":"2017","unstructured":"Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology. 2017;65:1393\u2013404.","journal-title":"Hepatology"},{"key":"1756_CR34","doi-asserted-by":"crossref","unstructured":"Khan S, Gaivin R, Abramovich C, Boylan M, Calles J, Schelling JR. Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression. JCI Insight. 2020;5:e136845.","DOI":"10.1172\/jci.insight.136845"},{"key":"1756_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11418-022-01647-w","volume":"77","author":"LS Ran","year":"2023","unstructured":"Ran LS, Wu YZ, Gan YW, Wang HL, Wu LJ, Zheng CM, et al. Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease. J Nat Med. 2023;77:73\u201386.","journal-title":"J Nat Med"},{"key":"1756_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202304408","volume":"11","author":"K Wu","year":"2024","unstructured":"Wu K, Liu Y, Xia J, Liu J, Wang K, Liang H, et al. Loss of SLC27A5 activates hepatic stellate cells and promotes liver fibrosis via unconjugated cholic acid. Adv Sci. 2024;11:e2304408.","journal-title":"Adv Sci"},{"key":"1756_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109701","volume":"36","author":"A Kumar","year":"2021","unstructured":"Kumar A, Cordes T, Thalacker-Mercer AE, Pajor AM, Murphy AN, Metallo CM. NaCT\/SLC13A5 facilitates citrate import and metabolism under nutrient-limited conditions. Cell Rep. 2021;36:109701.","journal-title":"Cell Rep"},{"key":"1756_CR38","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s42003-023-05311-1","volume":"6","author":"G Fern\u00e1ndez-Fuente","year":"2023","unstructured":"Fern\u00e1ndez-Fuente G, Overmyer KA, Lawton AJ, Kasza I, Shapiro SL, Gallego-Mu\u00f1oz P, et al. The citrate transporters SLC13A5 and SLC25A1 elicit different metabolic responses and phenotypes in the mouse. Commun Biol. 2023;6:926.","journal-title":"Commun Biol"},{"key":"1756_CR39","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jhep.2022.05.040","volume":"77","author":"N Bresciani","year":"2022","unstructured":"Bresciani N, Demagny H, Lemos V, Pontanari F, Li X, Sun Y, et al. The Slc25a47 locus is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis. J Hepatol. 2022;77:1071\u201382.","journal-title":"J Hepatol"},{"key":"1756_CR40","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1172\/JCI200421341","volume":"114","author":"K Kotani","year":"2004","unstructured":"Kotani K, Peroni OD, Minokoshi Y, Boss O, Kahn BB. GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. J Clin Invest. 2004;114:1666\u201375.","journal-title":"J Clin Invest."},{"key":"1756_CR41","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/78693","volume":"6","author":"A Zisman","year":"2000","unstructured":"Zisman A, Peroni OD, Abel ED, Michael MD, Mauvais-Jarvis F, Lowell BB, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med. 2000;6:924.","journal-title":"Nat Med"},{"key":"1756_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.908011","volume":"13","author":"Y Ni","year":"2022","unstructured":"Ni Y, Lu M, Xu Y, Wang Q, Gu X, Li Y, et al. The role of gut microbiota-bile acids axis in the progression of non-alcoholic fatty liver disease. Front Microbiol. 2022;13:908011.","journal-title":"Front Microbiol"},{"key":"1756_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","volume":"82","author":"CD Fuchs","year":"2025","unstructured":"Fuchs CD, Simbrunner B, Baumgartner M, Campbell C, Reiberger T, Trauner M. Bile acid metabolism and signalling in liver disease. J Hepatol. 2025;82:134\u201353.","journal-title":"J Hepatol"},{"key":"1756_CR44","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3748\/wjg.v19.i8.1158","volume":"19","author":"M Basaranoglu","year":"2013","unstructured":"Basaranoglu M, Basaranoglu G, Sent\u00fcrk H. From fatty liver to fibrosis: a tale of \u201csecond hit\u201d. World J Gastroenterol. 2013;19:1158\u201365.","journal-title":"World J Gastroenterol"},{"key":"1756_CR45","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00109-009-0464-1","volume":"87","author":"M Malaguarnera","year":"2009","unstructured":"Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med. 2009;87:679\u201395.","journal-title":"J Mol Med"},{"key":"1756_CR46","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.apsb.2023.09.004","volume":"14","author":"J Le","year":"2024","unstructured":"Le J, Chen Y, Yang W, Chen L, Ye J. Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus. Acta Pharm Sin B. 2024;14:437\u201354.","journal-title":"Acta Pharm Sin B"},{"key":"1756_CR47","doi-asserted-by":"crossref","unstructured":"Rebsamen M, Girardi E, Sedlyarov V, Scorzoni S, Papakostas K, Vollert M, et al. Gain-of-function genetic screens in human cells identify SLC transporters overcoming environmental nutrient restrictions. Life Sci Alliance. 2022;5:e202201404.","DOI":"10.26508\/lsa.202201404"},{"key":"1756_CR48","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41594-018-0076-y","volume":"25","author":"AA Garaeva","year":"2018","unstructured":"Garaeva AA, Oostergetel GT, Gati C, Guskov A, Paulino C, Slotboom DJ. Cryo-EM structure of the human neutral amino acid transporter ASCT2. Nat Struct Mol Biol. 2018;25:515\u201321.","journal-title":"Nat Struct Mol Biol"},{"key":"1756_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38720-1","volume":"14","author":"W Cui","year":"2023","unstructured":"Cui W, Niu Y, Sun Z, Liu R, Chen L. Structures of human SGLT in the occluded state reveal conformational changes during sugar transport. Nat Commun. 2023;14:2920.","journal-title":"Nat Commun"},{"key":"1756_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41594-023-01134-0","volume":"31","author":"M Hiraizumi","year":"2024","unstructured":"Hiraizumi M, Akashi T, Murasaki K, Kishida H, Kumanomidou T, Torimoto N, et al. Transport and inhibition mechanism of the human SGLT2\u2013MAP17 glucose transporter. Nat Struct Mol Biol. 2024;31:159\u201369.","journal-title":"Nat Struct Mol Biol"},{"key":"1756_CR51","doi-asserted-by":"crossref","unstructured":"Acharya R, Shetty SS, Pavan G, Monteiro F, Munikumar M, Naresh S, et al. AI-based homology modelling of fatty acid transport protein 1 using alphafold: structural elucidation and molecular dynamics exploration. Biomolecules. 2023;13:1670.","DOI":"10.3390\/biom13111670"},{"key":"1756_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52061-7","volume":"15","author":"G Zhou","year":"2024","unstructured":"Zhou G, Rusnac D-V, Park H, Canzani D, Nguyen HM, Stewart L, et al. An artificial intelligence accelerated virtual screening platform for drug discovery. Nat Commun. 2024;15:7761.","journal-title":"Nat Commun"},{"key":"1756_CR53","doi-asserted-by":"crossref","unstructured":"Zhang C, Yang X, Xue Y, Li H, Zeng C, Chen M. The role of solute carrier family transporters in hepatic steatosis and hepatic fibrosis. J Clin Transl Hepatol 2025;13:233\u201352.","DOI":"10.14218\/JCTH.2024.00348"},{"key":"1756_CR54","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.str.2025.02.012","volume":"33","author":"V B\u00e5genholm","year":"2025","unstructured":"B\u00e5genholm V, Nordlin KP, Pasquadibisceglie A, Belinskiy A, Holm CM, Hotiana HA, et al. Cryo-EM structure of the human monocarboxylate transporter 10. Structure. 2025;33:891\u2013902.e4.","journal-title":"Structure"},{"key":"1756_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202500227","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Zhang Z, Guan H, Zhu Q. Binding characterization of small molecule inhibitors to fatty acid transport protein 1: molecular docking and dynamics simulations. ChemistrySelect. 2025;10:e00227.","journal-title":"ChemistrySelect"},{"key":"1756_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23764-y","volume":"12","author":"E Smorodina","year":"2022","unstructured":"Smorodina E, Diankin I, Tao F, Qing R, Yang S, Zhang S. Structural informatics study of determined and AlphaFold2 predicted molecular structures of 13 human solute carrier transporters and their water-soluble QTY variants. Sci Rep. 2022;12:20103.","journal-title":"Sci Rep"},{"key":"1756_CR57","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.abj8754","volume":"373","author":"M Baek","year":"2021","unstructured":"Baek M, DiMaio F, Anishchenko I, Dauparas J, Ovchinnikov S, Lee GR, et al. Accurate prediction of protein structures and interactions using a three-track neural network. Science. 2021;373:871\u20136.","journal-title":"Science"},{"key":"1756_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102592","volume":"8","author":"H Su","year":"2021","unstructured":"Su H, Wang W, Du Z, Peng Z, Gao SH, Cheng MM, et al. Improved protein structure prediction using a new multi-scale network and homologous templates. Adv Sci. 2021;8:e2102592.","journal-title":"Adv Sci"},{"key":"1756_CR59","doi-asserted-by":"crossref","unstructured":"Jacobsen L, Lydersen L, Khandelia H. The ATP-bound state of the uncoupling protein 1 (UCP1) from molecular simulations. J Phys Chem B. 2023;127:9685\u201396.","DOI":"10.1021\/acs.jpcb.3c03473"},{"key":"1756_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s13721-025-00524-2","volume":"14","author":"E Karami","year":"2025","unstructured":"Karami E, Rostamkhani F, Abdollahi M, Ahmadifard M. Computational insights into human UCP1 activation by wide virtual screening as a new anti-obesity: a study utilizing molecular docking and molecular dynamics simulations. Netw ModelAnal Health Inform Bioinform. 2025;14:32.","journal-title":"Netw ModelAnal Health Inform Bioinform"},{"key":"1756_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2024.108252","volume":"113","author":"UA Jagtap","year":"2024","unstructured":"Jagtap UA, Rathod S, Shukla R, Paul AT. Computational insights into human UCP1 activators through molecular docking, MM-GBSA, and molecular dynamics simulation studies. Comput Biol Chem. 2024;113:108252.","journal-title":"Comput Biol Chem"},{"key":"1756_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108466","volume":"161","author":"H Gong","year":"2025","unstructured":"Gong H, Qi Y, Wu X, Wu L, Liu W, Chen H, et al. UCP1-inspired mitochondrial uncouplers: design, synthesis and thermogenic activity studies. Bioorg Chem. 2025;161:108466.","journal-title":"Bioorg Chem"},{"key":"1756_CR63","doi-asserted-by":"crossref","unstructured":"Mazoudji A, Ecker GF. Docking-based classification of SGLT2 inhibitors. Molecules. 2025;30:2179.","DOI":"10.3390\/molecules30102179"},{"key":"1756_CR64","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.cell.2023.04.010","volume":"186","author":"I Singh","year":"2023","unstructured":"Singh I, Seth A, Billesb\u00f8lle CB, Braz J, Rodriguiz RM, Roy K, et al. Structure-based discovery of conformationally selective inhibitors of the serotonin transporter. Cell. 2023;186:2160\u201375.e17.","journal-title":"Cell"},{"key":"1756_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37572-z","volume":"14","author":"A Chatterjee","year":"2023","unstructured":"Chatterjee A, Walters R, Shafi Z, Ahmed OS, Sebek M, Gysi D, et al. Improving the generalizability of protein-ligand binding predictions with AI-Bind. Nat Commun. 2023;14:1989.","journal-title":"Nat Commun"},{"key":"1756_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30126-9","volume":"13","author":"X Shi","year":"2022","unstructured":"Shi X, Reinstadler B, Shah H, To T-L, Byrne K, Summer L, et al. Combinatorial GxGxE CRISPR screen identifies SLC25A39 in mitochondrial glutathione transport linking iron homeostasis to OXPHOS. Nat Commun. 2022;13:2483.","journal-title":"Nat Commun"},{"key":"1756_CR67","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s44320-025-00105-5","volume":"21","author":"G Wolf","year":"2025","unstructured":"Wolf G, Leippe P, Onstein S, Goldmann U, Frommelt F, Teoh ST, et al. The genetic interaction map of the human solute carrier superfamily. Mol Syst Biol. 2025;21:531\u201359.","journal-title":"Mol Syst Biol"},{"key":"1756_CR68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2337\/db18-0525","volume":"68","author":"DD Shuboni-Mulligan","year":"2019","unstructured":"Shuboni-Mulligan DD, Parys M, Blanco-Fernandez B, Mallett CL, Schnegelberger R, Takada M, et al. Dynamic contrast-enhanced MRI of OATP dysfunction in diabetes. Diabetes. 2019;68:271\u201380.","journal-title":"Diabetes"},{"key":"1756_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13576","volume":"57","author":"Y Liang","year":"2024","unstructured":"Liang Y, Zhang R, Biswas S, Bu Q, Xu Z, Qiao L, et al. Integrated single-cell transcriptomics reveals the hypoxia-induced inflammation-cancer transformation in NASH-derived hepatocellular carcinoma. Cell Prolif. 2024;57:e13576.","journal-title":"Cell Prolif"},{"key":"1756_CR70","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1096\/fj.14-250555","volume":"28","author":"C Kampf","year":"2014","unstructured":"Kampf C, Mardinoglu A, Fagerberg L, Hallstr\u00f6m BM, Edlund K, Lundberg E, et al. The human liver-specific proteome defined by transcriptomics and antibody-based profiling. FASEB J. 2014;28:2901\u201314.","journal-title":"FASEB J."},{"key":"1756_CR71","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1021\/acscentsci.0c00518","volume":"6","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Shen Y, Wen Y, Campbell RE. High-performance intensiometric direct- and inverse-response genetically encoded biosensors for citrate. ACS Cent Sci. 2020;6:1441\u201350.","journal-title":"ACS Cent Sci"},{"key":"1756_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101526","volume":"62","author":"R Cavalieri","year":"2022","unstructured":"Cavalieri R, Hazebroek MK, Cotrim CA, Lee Y, Kunji ERS, Jastroch M, et al. Activating ligands of Uncoupling protein 1 identified by rapid membrane protein thermostability shift analysis. Mol Metab. 2022;62:101526.","journal-title":"Mol Metab"},{"key":"1756_CR73","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","volume":"11","author":"P Rada","year":"2020","unstructured":"Rada P, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C, Valverde \u00c1M. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis. 2020;11:802.","journal-title":"Cell Death Dis"},{"key":"1756_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156462","volume":"175","author":"Y Zhou","year":"2026","unstructured":"Zhou Y, Dai Y, Qin M, Li Y, Shi L, Chen H, et al. FAM83A acts as an amplifier for lipogenic signaling to facilitate the pathogenesis of metabolic dysfunction-associated steatohepatitis. Metabolism. 2026;175:156462.","journal-title":"Metabolism"},{"key":"1756_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.149161","volume":"687","author":"H Li","year":"2023","unstructured":"Li H, Seessle J, Staffer S, Tuma-Kellner S, Poschet G, Herrmann T, et al. FATP4 deletion in liver cells induces elevation of extracellular lipids via metabolic channeling towards triglycerides and lipolysis. Biochem Biophys Res Commun. 2023;687:149161.","journal-title":"Biochem Biophys Res Commun"},{"key":"1756_CR76","doi-asserted-by":"crossref","unstructured":"Seessle J, Liebisch G, Schmitz G, Stremmel W, Chamulitrat W. Compositional changes among triglycerides and phospholipids during FATP4 sensitization with palmitate lead to ER stress in cultured cells. Eur J lipid Sci Technol. 2019;121:1800394.","DOI":"10.1002\/ejlt.201800394"},{"key":"1756_CR77","doi-asserted-by":"crossref","unstructured":"Zak\u0142os-Szyda M, Pietrzyk N, Kowalska-Baron A, Nowak A, Cha\u0142a\u015bkiewicz K, Ratajewski M, et al. Phenolics-rich extracts of dietary plants as regulators of fructose uptake in Caco-2 cells via Glut5 involvement. Molecules. 2021;26:4745.","DOI":"10.3390\/molecules26164745"},{"key":"1756_CR78","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00535-019-01633-2","volume":"55","author":"K Enooku","year":"2020","unstructured":"Enooku K, Tsutsumi T, Kondo M, Fujiwara N, Sasako T, Shibahara J, et al. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. J Gastroenterol. 2020;55:227\u201343.","journal-title":"J Gastroenterol"},{"key":"1756_CR79","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1038\/s41418-020-0491-6","volume":"27","author":"M Tan","year":"2020","unstructured":"Tan M, Mosaoa R, Graham GT, Kasprzyk-Pawelec A, Gadre S, Parasido E, et al. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD\/NASH. Cell Death Differ. 2020;27:2143\u201357.","journal-title":"Cell Death Differ"},{"key":"1756_CR80","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.ajpath.2022.06.002","volume":"192","author":"N Roy","year":"2022","unstructured":"Roy N, Alencastro F, Roseman BA, Wilson SR, Delgado ER, May MC, et al. Dysregulation of lipid and glucose homeostasis in hepatocyte-specific SLC25A34 knockout mice. Am J Pathol. 2022;192:1259\u201381.","journal-title":"Am J Pathol"},{"key":"1756_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20461-0","volume":"12","author":"J-H Kim","year":"2021","unstructured":"Kim J-H, Matsubara T, Lee J, Fenollar-Ferrer C, Han K, Kim D, et al. Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis. Nat Commun. 2021;12:290.","journal-title":"Nat Commun"},{"key":"1756_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.149922","volume":"712-713","author":"T Yamamoto","year":"2024","unstructured":"Yamamoto T, Iizuka Y, Izumi-Yamamoto K, Shirota M, Mori N, Tahara Y, et al. Overexpression of Slc22a18 facilitates fat accumulation in mice. Biochem Biophys Res Commun. 2024;712-713:149922.","journal-title":"Biochem Biophys Res Commun"},{"key":"1756_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47269-4","volume":"13","author":"P Zeng","year":"2023","unstructured":"Zeng P, Cai X, Yu X, Gong L. Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population. Sci Rep. 2023;13:20470.","journal-title":"Sci Rep"},{"key":"1756_CR84","doi-asserted-by":"crossref","unstructured":"Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22:4156.","DOI":"10.3390\/ijms22084156"},{"key":"1756_CR85","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-021-04211-w","volume":"601","author":"L Han","year":"2022","unstructured":"Han L, Qu Q, Aydin D, Panova O, Robertson MJ, Xu Y, et al. Structure and mechanism of the SGLT family of glucose transporters. Nature. 2022;601:274\u20139.","journal-title":"Nature"},{"key":"1756_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30235-5","volume":"13","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Kong F, Xu H, Zhu A, Yan N, Yan C. Cryo-EM structure of human glucose transporter GLUT4. Nat Commun. 2022;13:2671.","journal-title":"Nat Commun"},{"key":"1756_CR87","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4331\/wjbc.v11.i3.76","volume":"11","author":"T Wang","year":"2020","unstructured":"Wang T, Wang J, Hu X, Huang XJ, Chen GX. Current understanding of glucose transporter 4 expression and functional mechanisms. World J Biol Chem. 2020;11:76\u201398.","journal-title":"World J Biol Chem"},{"key":"1756_CR88","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1134\/S0006297921110055","volume":"86","author":"W Lin","year":"2021","unstructured":"Lin W, Jin Y, Hu X, Huang E, Zhu Q. AMPK\/PGC-1\u03b1\/GLUT4-mediated effect of icariin on hyperlipidemia-induced non-alcoholic fatty liver disease and lipid metabolism disorder in mice.\u00a0Biochemistry (Mosc). 2021;86:1407\u201317.","journal-title":"Biochemistry (Mosc)."},{"key":"1756_CR89","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","volume":"45","author":"AJ Scheen","year":"2019","unstructured":"Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. Diabetes Metab. 2019;45:213\u201323.","journal-title":"Diabetes Metab"},{"key":"1756_CR90","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","volume":"80","author":"KS Cheung","year":"2024","unstructured":"Cheung KS, Ng HY, Hui RWH, Lam LK, Mak LY, Ho YC, et al. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Hepatology. 2024;80:916\u201327.","journal-title":"Hepatology"},{"key":"1756_CR91","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/s41401-024-01389-3","volume":"45","author":"X-f Lin","year":"2024","unstructured":"Lin XF, Cui XN, Yang J, Jiang YF, Wei TJ, Xia L, et al. SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization. Acta Pharmacol Sin. 2024;45:2579\u201397.","journal-title":"Acta Pharmacol Sin."},{"key":"1756_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108650","volume":"38","author":"S Wakamatsu","year":"2024","unstructured":"Wakamatsu S, Jojima T, Hashiguchi M, Kishi H, Niitani T, Sakurai S, et al. Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor. J Diabetes Complicat. 2024;38:108650.","journal-title":"J Diabetes Complicat"},{"key":"1756_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109789","volume":"185","author":"TV Fiorentino","year":"2022","unstructured":"Fiorentino TV, De Vito F, Suraci E, Marasco R, Catalano F, Andreozzi F, et al. Augmented duodenal levels of sodium\/glucose co-transporter 1 are associated with higher risk of nonalcoholic fatty liver disease and noninvasive index of liver fibrosis. Diabetes Res Clin Pract. 2022;185:109789.","journal-title":"Diabetes Res Clin Pract"},{"key":"1756_CR94","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jphs.2021.07.002","volume":"147","author":"Y Honda","year":"2021","unstructured":"Honda Y, Ozaki A, Iwaki M, Kobayashi T, Nogami A, Kessoku T, et al. Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice. J Pharmacol Sci. 2021;147:176\u201383.","journal-title":"J Pharmacol Sci"},{"key":"1756_CR95","doi-asserted-by":"crossref","unstructured":"Weng Y, Fonseca KR, Bi YA, Mathialagan S, Riccardi K, Tseng E, et al. Transporter-enzyme interplay in the pharmacokinetics of PF-06835919, a first-in-class ketohexokinase inhibitor for metabolic disorders and non-alcoholic fatty liver disease. Drug Metab Dispos. 2022;50:1312\u201321.","DOI":"10.1124\/dmd.122.000953"},{"key":"1756_CR96","doi-asserted-by":"crossref","unstructured":"Ramanathan R, Ali AH, Ibdah JA. Mitochondrial dysfunction plays central role in nonalcoholic fatty liver disease. Int J Mol Sci. 2022;23:7280.","DOI":"10.3390\/ijms23137280"},{"key":"1756_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04367-1","volume":"21","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Wang S, Wu J, Wang Y. Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy. J Transl Med. 2023;21:510.","journal-title":"J Transl Med"},{"key":"1756_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac002","volume":"4","author":"MJ Rigby","year":"2022","unstructured":"Rigby MJ, Orefice NS, Lawton AJ, Ma M, Shapiro SL, Yi SY, et al. SLC13A5\/sodium-citrate co-transporter overexpression causes disrupted white matter integrity and an autistic-like phenotype. Brain Commun. 2022;4:fcac002.","journal-title":"Brain Commun"},{"key":"1756_CR99","doi-asserted-by":"crossref","unstructured":"Zahn G, Willmes DM, El-Agroudy NN, Yarnold C, Jarjes-Pike R, Schaertl S, et al. A novel and cross-species active mammalian INDY (NaCT) inhibitor ameliorates hepatic steatosis in mice with diet-induced obesity. Metabolites. 2022;12:732.","DOI":"10.3390\/metabo12080732"},{"key":"1756_CR100","doi-asserted-by":"publisher","first-page":"8714","DOI":"10.1021\/acs.jafc.1c03105","volume":"69","author":"Q Sun","year":"2021","unstructured":"Sun Q, Niu Q, Guo Y, Zhuang Y, Li X, Liu J, et al. Regulation on citrate influx and metabolism through inhibiting SLC13A5 and ACLY: a novel mechanism mediating the therapeutic effects of curcumin on NAFLD. J Agric Food Chem. 2021;69:8714\u201325.","journal-title":"J Agric Food Chem"},{"key":"1756_CR101","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1042\/BCJ20200592","volume":"477","author":"K Higuchi","year":"2020","unstructured":"Higuchi K, Kopel JJ, Sivaprakasam S, Jaramillo-Mart\u00ednez V, Sutton RB, Urbatsch IL, et al. Functional analysis of a species-specific inhibitor selective for human Na+-coupled citrate transporter (NaCT\/SLC13A5\/mINDY). Biochem J. 2020;477:4149\u201365.","journal-title":"Biochem J"},{"key":"1756_CR102","doi-asserted-by":"publisher","first-page":"6687","DOI":"10.1021\/acs.jmedchem.4c00260","volume":"67","author":"LA Zhang","year":"2024","unstructured":"Zhang LA, Hu W, Guo H, Sun Q, Xu X, Li Z, et al. Discovery of highly potent solute carrier 13 member 5 (SLC13A5) inhibitors for the treatment of hyperlipidemia. J Med Chem. 2024;67:6687\u2013704.","journal-title":"J Med Chem"},{"key":"1756_CR103","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s44318-025-00362-y","volume":"44","author":"L Shi","year":"2025","unstructured":"Shi L, Chen H, Zhang Y, An D, Qin M, Yu W, et al. SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis. EMBO J. 2025;44:1442\u201363.","journal-title":"EMBO J"},{"key":"1756_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113740","volume":"431","author":"T Nakanishi","year":"2023","unstructured":"Nakanishi T, Kawasaki Y, Nakamura Y, Kimura Y, Kawamura K, Shumba MN, et al. An implication of the mitochondrial carrier SLC25A3 as an oxidative stress modulator in NAFLD. Exp Cell Res. 2023;431:113740.","journal-title":"Exp Cell Res"},{"key":"1756_CR105","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1007\/s12011-023-04057-5","volume":"202","author":"ZB Aksoy-Ozer","year":"2024","unstructured":"Aksoy-Ozer ZB, Bitirim CV, Turan B, Akcali KC. The role of zinc on liver fibrosis by modulating ZIP14 expression throughout epigenetic regulatory mechanisms. Biol Trace Elem Res. 2024;202:5094\u2013105.","journal-title":"Biol Trace Elem Res"},{"key":"1756_CR106","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s42255-021-00389-5","volume":"3","author":"EL Mills","year":"2021","unstructured":"Mills EL, Harmon C, Jedrychowski MP, Xiao H, Garrity R, Tran NV, et al. UCP1 governs liver extracellular succinate and inflammatory pathogenesis. Nat Metab. 2021;3:604\u201317.","journal-title":"Nat Metab"},{"key":"1756_CR107","doi-asserted-by":"crossref","unstructured":"Mostafavi Abdolmaleky H, Zhou JR. Gut microbiota dysbiosis, oxidative stress, inflammation, and epigenetic alterations in metabolic diseases. Antioxidants. 2024;13:985.","DOI":"10.3390\/antiox13080985"},{"key":"1756_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72909-8","volume":"14","author":"C Yang","year":"2024","unstructured":"Yang C, Wu J, Yang L, Hu Q, Li L, Yang Y, et al. Altered gut microbial profile accompanied by abnormal short-chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression. Sci Rep. 2024;14:22385.","journal-title":"Sci Rep"},{"key":"1756_CR109","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s42255-024-00981-5","volume":"6","author":"A Reddy","year":"2024","unstructured":"Reddy A, Winther S, Tran N, Xiao H, Jakob J, Garrity R, et al. Monocarboxylate transporters facilitate succinate uptake into brown adipocytes. Nat Metab. 2024;6:567\u201377.","journal-title":"Nat Metab"},{"key":"1756_CR110","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12072-020-10107-0","volume":"15","author":"R Yamauchi","year":"2021","unstructured":"Yamauchi R, Takedatsu H, Yokoyama K, Yamauchi E, Kawashima M, Nagata T, et al. Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice. Hepatol Int. 2021;15:392\u2013404.","journal-title":"Hepatol Int"},{"key":"1756_CR111","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01155-21","volume":"12","author":"M Matsui","year":"2021","unstructured":"Matsui M, Fukunishi S, Nakano T, Ueno T, Higuchi K, Asai A. Ileal bile acid transporter inhibitor improves hepatic steatosis by ameliorating gut microbiota dysbiosis in NAFLD model mice. mBio. 2021;12:e0115521.","journal-title":"mBio"},{"key":"1756_CR112","unstructured":"A double-blind, randomized, placebo-controlled, phase 2 study to explore the efficacy and safety of elobixibat in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04006145."},{"key":"1756_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2023.109434","volume":"121","author":"D Zhang","year":"2023","unstructured":"Zhang D, Wang H, Liu A, Wang S, Xu C, Lan K, et al. The chronic consumption of dietary fructose promotes the gut Clostridium species imbalance and bile acid alterations in developing nonalcoholic fatty liver disease. J Nutr Biochem. 2023;121:109434.","journal-title":"J Nutr Biochem"},{"key":"1756_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101411","volume":"55","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Nagoshi T, Takahashi H, Oi Y, Yoshii A, Kimura H, et al. URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice. Mol Metab. 2022;55:101411.","journal-title":"Mol Metab"},{"key":"1756_CR115","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/oby.22110","volume":"26","author":"Z Song","year":"2018","unstructured":"Song Z, Revelo X, Shao W, Tian L, Zeng K, Lei H, et al. Dietary curcumin intervention targets mouse white adipose tissue inflammation and brown adipose tissue UCP1 expression. Obes. 2018;26:547\u201358.","journal-title":"Obes"},{"key":"1756_CR116","doi-asserted-by":"crossref","unstructured":"Islam T, Katasani G, Koboziev I, Albracht-Schulte K, Scoggin S, Ramalingam L, et al. Curcumin reduces hepatic and white adipose tissue inflammation and expression of specific zinc transporters in diet-induced obese mice. Curr Dev Nutr. 2021;5:325.","DOI":"10.1093\/cdn\/nzab037_035"},{"key":"1756_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202100274","volume":"65","author":"T Islam","year":"2021","unstructured":"Islam T, Koboziev I, Albracht-Schulte K, Mistretta B, Scoggin S, Yosofvand M, et al. Curcumin reduces adipose tissue inflammation and alters gut microbiota in diet-induced obese male mice. Mol Nutr Food Res. 2021;65:e2100274.","journal-title":"Mol Nutr Food Res"},{"key":"1756_CR118","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","volume":"28","author":"SA Harrison","year":"2022","unstructured":"Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, et al. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med. 2022;28:1432\u20138.","journal-title":"Nat Med"},{"key":"1756_CR119","doi-asserted-by":"publisher","first-page":"15613","DOI":"10.1073\/pnas.2536196100","volume":"100","author":"CW Heilig","year":"2003","unstructured":"Heilig CW, Saunders T, Brosius FC 3rd, Moley K, Heilig K, Baggs R, et al. Glucose transporter-1-deficient mice exhibit impaired development and deformities that are similar to diabetic embryopathy. Proc Natl Acad Sci USA. 2003;100:15613\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1756_CR120","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/hep.26052","volume":"57","author":"M Vazquez-Chantada","year":"2013","unstructured":"Vazquez-Chantada M, Gonzalez-Lahera A, Martinez-Arranz I, Garcia-Monzon C, Regueiro MM, Garcia-Rodriguez JL, et al. Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease. Hepatology. 2013;57:505\u201314.","journal-title":"Hepatology"},{"key":"1756_CR121","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0014-5793(02)03058-2","volume":"524","author":"M Uldry","year":"2002","unstructured":"Uldry M, Ibberson M, Hosokawa M, Thorens B. GLUT2 is a high-affinity glucosamine transporter. FEBS Lett. 2002;524:199\u2013203.","journal-title":"FEBS Lett"},{"key":"1756_CR122","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/09687680110072131","volume":"18","author":"H Wallberg-Henriksson","year":"2001","unstructured":"Wallberg-Henriksson H, Zierath JR. GLUT4: a key player regulating glucose homeostasis? Insights from transgenic and knockout mice (review). Mol Membr Biol. 2001;18:205\u201311.","journal-title":"Mol Membr Biol"},{"key":"1756_CR123","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.cmet.2021.09.010","volume":"33","author":"MA Herman","year":"2021","unstructured":"Herman MA, Birnbaum MJ. Molecular aspects of fructose metabolism and metabolic disease. Cell Metab. 2021;33:2329\u201354.","journal-title":"Cell Metab"},{"key":"1756_CR124","first-page":"109","volume":"4","author":"M Basaranoglu","year":"2015","unstructured":"Basaranoglu M, Basaranoglu G, Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015;4:109\u201316.","journal-title":"Hepatobiliary Surg Nutr."},{"key":"1756_CR125","doi-asserted-by":"publisher","first-page":"10989","DOI":"10.1074\/jbc.M113.527002","volume":"289","author":"BJ DeBosch","year":"2014","unstructured":"DeBosch BJ, Chen Z, Saben JL, Finck BN, Moley KH. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis. J Biol Chem. 2014;289:10989\u201398.","journal-title":"J Biol Chem"},{"key":"1756_CR126","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1210\/me.2013-1137","volume":"27","author":"BJ DeBosch","year":"2013","unstructured":"DeBosch BJ, Chen Z, Finck BN, Chi M, Moley KH. Glucose transporter-8 (GLUT8) mediates glucose intolerance and dyslipidemia in high-fructose diet-fed male mice. Mol Endocrinol. 2013;27:1887\u201396.","journal-title":"Mol Endocrinol"},{"key":"1756_CR127","doi-asserted-by":"publisher","first-page":"15501","DOI":"10.1073\/pnas.0904411106","volume":"106","author":"F Preitner","year":"2009","unstructured":"Preitner F, Bonny O, Laverri\u00e8re A, Rotman S, Firsov D, Da Costa A, et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci USA. 2009;106:15501\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1756_CR128","doi-asserted-by":"publisher","first-page":"E1032","DOI":"10.1152\/ajpendo.00518.2020","volume":"320","author":"D Xie","year":"2021","unstructured":"Xie D, Zhao H, Lu J, He F, Liu W, Yu W, et al. High uric acid induces liver fat accumulation via ROS\/JNK\/AP-1 signaling. Am J Physiol Endocrinol Metab. 2021;320:E1032\u2013e43.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1756_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19658-7","volume":"8","author":"K Shiba","year":"2018","unstructured":"Shiba K, Tsuchiya K, Komiya C, Miyachi Y, Mori K, Shimazu N, et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep. 2018;8:2362.","journal-title":"Sci Rep"},{"key":"1756_CR130","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/21623945.2021.1979277","volume":"10","author":"T Han","year":"2021","unstructured":"Han T, Fan Y, Gao J, Fatima M, Zhang Y, Ding Y, et al. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet-induced obese mice. Adipocyte. 2021;10:446\u201355.","journal-title":"Adipocyte"},{"key":"1756_CR131","doi-asserted-by":"publisher","first-page":"e56681","DOI":"10.1371\/journal.pone.0056681","volume":"8","author":"T Fukuzawa","year":"2013","unstructured":"Fukuzawa T, Fukazawa M, Ueda O, Shimada H, Kito A, Kakefuda M, et al. SGLT5 reabsorbs fructose in the kidney, but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose. PLoS One. 2013;8:e56681.","journal-title":"PLoS One."},{"key":"1756_CR132","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00424-005-1487-2","volume":"451","author":"AM Pajor","year":"2006","unstructured":"Pajor AM. Molecular properties of the SLC13 family of dicarboxylate and sulfate transporters. Pflug Arch. 2006;451:597\u2013605.","journal-title":"Pflug Arch"},{"key":"1756_CR133","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1152\/physiolgenomics.00300.2005","volume":"26","author":"PA Dawson","year":"2006","unstructured":"Dawson PA, Gardiner B, Grimmond S, Markovich D. Transcriptional profile reveals altered hepatic lipid and cholesterol metabolism in hyposulfatemic NaS1 null mice. Physiol Genom. 2006;26:116\u201324.","journal-title":"Physiol Genom"},{"key":"1756_CR134","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s00424-003-1128-6","volume":"447","author":"D Markovich","year":"2004","unstructured":"Markovich D, Murer H. The SLC13 gene family of sodium sulphate\/carboxylate cotransporters. Pflug Arch. 2004;447:594\u2013602.","journal-title":"Pflug Arch"},{"key":"1756_CR135","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fimmu.2018.00141","volume":"9","author":"NC Williams","year":"2018","unstructured":"Williams NC, O\u2019Neill LAJ. A role for the Krebs cycle intermediate citrate in metabolic reprogramming in innate immunity and inflammation. Front Immunol. 2018;9:141.","journal-title":"Front Immunol"},{"key":"1756_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03397-y","volume":"23","author":"SI Hussain","year":"2023","unstructured":"Hussain SI, Muhammad N, Shah SUD, Fardous F, Khan SA, Khan N, et al. Structural and functional implications of SLC13A3 and SLC9A6 mutations: an in silico approach to understanding intellectual disability. BMC Neurol. 2023;23:353.","journal-title":"BMC Neurol"},{"key":"1756_CR137","doi-asserted-by":"crossref","unstructured":"Bhutia YD, Kopel JJ, Lawrence JJ, Neugebauer V, Ganapathy V. Plasma membrane Na+-coupled citrate transporter (SLC13A5) and neonatal epileptic encephalopathy. Molecules. 2017;22:378.","DOI":"10.3390\/molecules22030378"},{"key":"1756_CR138","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/iub.572","volume":"64","author":"AP Halestrap","year":"2012","unstructured":"Halestrap AP, Wilson MC. The monocarboxylate transporter family-role and regulation. IUBMB Life. 2012;64:109\u201319.","journal-title":"IUBMB Life"},{"key":"1756_CR139","doi-asserted-by":"crossref","unstructured":"Dro\u017adzik M, Szel\u0105g-Pieniek S, Grzeg\u00f3\u0142kowska J, \u0141apczuk-Roma\u0144ska J, Post M, Domaga\u0142a P, et al. Monocarboxylate transporter 1 (MCT1) in liver pathology. Int J Mol Sci. 2020;21:1606.","DOI":"10.3390\/ijms21051606"},{"key":"1756_CR140","doi-asserted-by":"publisher","first-page":"778","DOI":"10.5301\/JN.2011.6382","volume":"24","author":"FE Lokman","year":"2011","unstructured":"Lokman FE, Seman NA, Ismail AA, Yaacob NA, Mustafa N, Khir AS, et al. Gene expression profiling in ethnic Malays with type 2 diabetes mellitus, with and without diabetic nephropathy. J Nephrol. 2011;24:778\u201389.","journal-title":"J Nephrol"},{"key":"1756_CR141","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000521034","volume":"89","author":"SC Granja","year":"2022","unstructured":"Granja SC, Longatto-Filho A, de Campos PB, Oliveira CP, Stefano JT, Martins-Filho SN, et al. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: immunohistochemical assessment of markers of cancer cell metabolism. Pathobiology. 2022;89:157\u201365.","journal-title":"Pathobiology"},{"key":"1756_CR142","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1113\/jphysiol.2012.239574","volume":"590","author":"L Mariotta","year":"2012","unstructured":"Mariotta L, Ramadan T, Singer D, Guetg A, Herzog B, Stoeger C, et al. T-type amino acid transporter TAT1 (Slc16a10) is essential for extracellular aromatic amino acid homeostasis control. J Physiol. 2012;590:6413.","journal-title":"J Physiol"},{"key":"1756_CR143","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hep.29465","volume":"67","author":"M Gaggini","year":"2018","unstructured":"Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, et al. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. Hepatology. 2018;67:145\u201358.","journal-title":"Hepatology"},{"key":"1756_CR144","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/a-0840-3330","volume":"129","author":"T Zhang","year":"2021","unstructured":"Zhang T, Qi Z, Wang H, Ding S. Adeno-associated virus-mediated knockdown of SLC16A11 improves glucose tolerance and hepatic insulin signaling in high-fat diet-fed mice. Exp Clin Endocrinol Diabetes. 2021;129:104\u201311.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1756_CR145","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s42003-021-02279-8","volume":"4","author":"T Schumann","year":"2021","unstructured":"Schumann T, K\u00f6nig J, von Loeffelholz C, Vatner DF, Zhang D, Perry RJ, et al. Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance. Commun Biol. 2021;4:826.","journal-title":"Commun Biol"},{"key":"1756_CR146","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/bdd.1816","volume":"34","author":"I Tamai","year":"2013","unstructured":"Tamai I. Pharmacological and pathophysiological roles of carnitine\/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm Drug Dispos. 2013;34:29\u201344.","journal-title":"Biopharm Drug Dispos"},{"key":"1756_CR147","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12098-016-2227-7","volume":"84","author":"S Deswal","year":"2017","unstructured":"Deswal S, Bijarnia-Mahay S, Manocha V, Hara K, Shigematsu Y, Saxena R, et al. Primary carnitine deficiency\u2014 a rare treatable cause of cardiomyopathy and massive hepatomegaly. Indian J Pediatr. 2017;84:83\u20135.","journal-title":"Indian J Pediatr"},{"key":"1756_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113829","volume":"174","author":"S Mathialagan","year":"2020","unstructured":"Mathialagan S, Bi YA, Costales C, Kalgutkar AS, Rodrigues AD, Varma MVS. Nicotinic acid transport into the human liver involves organic anion transporter 2 (SLC22A7). Biochem Pharmacol. 2020;174:113829.","journal-title":"Biochem Pharmacol"},{"key":"1756_CR149","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1113\/JP280908","volume":"600","author":"M Dall","year":"2022","unstructured":"Dall M, Hassing AS, Treebak JT. NAD+ and NAFLD - caution, causality and careful optimism. J Physiol. 2022;600:1135\u201354.","journal-title":"J Physiol."},{"key":"1756_CR150","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/hep.21596","volume":"45","author":"HJ Shin","year":"2007","unstructured":"Shin HJ, Anzai N, Enomoto A, He X, Kim DK, Endou H, et al. Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short-chain fatty acid butyrate. Hepatology. 2007;45:1046\u201355.","journal-title":"Hepatology"},{"key":"1756_CR151","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1124\/mol.110.065201","volume":"78","author":"K Klein","year":"2010","unstructured":"Klein K, J\u00fcngst C, Mwinyi J, Stieger B, Krempler F, Patsch W, et al. The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1\u03b1 (HNF-1\u03b1). Mol Pharmacol. 2010;78:1079\u201387.","journal-title":"Mol Pharmacol"},{"key":"1756_CR152","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.molmet.2017.04.008","volume":"6","author":"N Seshadri","year":"2017","unstructured":"Seshadri N, Jonasson ME, Hunt KL, Xiang B, Cooper S, Wheeler MB, et al. Uncoupling protein 2 regulates daily rhythms of insulin secretion capacity in MIN6 cells and isolated islets from male mice. Mol Metab. 2017;6:760\u20139.","journal-title":"Mol Metab"},{"key":"1756_CR153","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/1873-3468.13546","volume":"593","author":"J Li","year":"2019","unstructured":"Li J, Jiang R, Cong X, Zhao Y. UCP2 gene polymorphisms in obesity and diabetes, and the role of UCP2 in cancer. FEBS Lett. 2019;593:2525\u201334.","journal-title":"FEBS Lett"},{"key":"1756_CR154","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000233249","volume":"24","author":"Y Camara","year":"2009","unstructured":"Camara Y, Mampel T, Armengol J, Villarroya F, Dejean L. UCP3 expression in liver modulates gene expression and oxidative metabolism in response to fatty acids, and sensitizes mitochondria to permeability transition. Cell Physiol Biochem. 2009;24:243\u201352.","journal-title":"Cell Physiol Biochem"},{"key":"1756_CR155","doi-asserted-by":"publisher","first-page":"32434","DOI":"10.1074\/jbc.M503152200","volume":"280","author":"S Mizuarai","year":"2005","unstructured":"Mizuarai S, Miki S, Araki H, Takahashi K, Kotani H. Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis. J Biol Chem. 2005;280:32434\u201341.","journal-title":"J Biol Chem"},{"key":"1756_CR156","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jhep.2021.03.006","volume":"75","author":"YA An","year":"2021","unstructured":"An YA, Chen S, Deng Y, Wang ZV, Funcke JB, Shah M, et al. The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. J Hepatol. 2021;75:387\u201399.","journal-title":"J Hepatol"},{"key":"1756_CR157","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.abb.2008.03.008","volume":"474","author":"Q Zhong","year":"2008","unstructured":"Zhong Q, Putt DA, Xu F, Lash LH. Hepatic mitochondrial transport of glutathione: studies in isolated rat liver mitochondria and H4IIE rat hepatoma cells. Arch Biochem Biophys. 2008;474:119\u201327.","journal-title":"Arch Biochem Biophys"},{"key":"1756_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66837-6","volume":"10","author":"G Pan","year":"2020","unstructured":"Pan G, Wang R, Jia S, Li Y, Jiao Y, Liu N. SLC25A11 serves as a novel prognostic biomarker in liver cancer. Sci Rep. 2020;10:9871.","journal-title":"Sci Rep"},{"key":"1756_CR159","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.hepres.2005.09.031","volume":"33","author":"T Saheki","year":"2005","unstructured":"Saheki T, Kobayashi K, Iijima M, Moriyama M, Yazaki M, Takei Y, et al. Metabolic derangements in deficiency of citrin, a liver-type mitochondrial aspartate-glutamate carrier. Hepatol Res. 2005;33:181\u20134.","journal-title":"Hepatol Res"},{"key":"1756_CR160","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jhep.2008.05.016","volume":"49","author":"M Komatsu","year":"2008","unstructured":"Komatsu M, Yazaki M, Tanaka N, Sano K, Hashimoto E, Takei Y, et al. Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. J Hepatol. 2008;49:810\u201320.","journal-title":"J Hepatol"},{"key":"1756_CR161","doi-asserted-by":"crossref","unstructured":"Tonazzi A, Giangregorio N, Console L, Palmieri F, Indiveri C. The mitochondrial carnitine Acyl-carnitine carrier (SLC25A20): molecular mechanisms of transport, role in redox sensing and interaction with drugs. Biomolecules. 2021;11:521.","DOI":"10.3390\/biom11040521"},{"key":"1756_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/srep45383","volume":"7","author":"SP Harborne","year":"2017","unstructured":"Harborne SP, King MS, Crichton PG, Kunji ER. Calcium regulation of the human mitochondrial ATP-Mg\/Pi carrier SLC25A24 uses a locking pin mechanism. Sci Rep. 2017;7:45383.","journal-title":"Sci Rep"},{"key":"1756_CR163","doi-asserted-by":"publisher","first-page":"E655","DOI":"10.1210\/jc.2014-2829","volume":"100","author":"T Urano","year":"2015","unstructured":"Urano T, Shiraki M, Sasaki N, Ouchi Y, Inoue S. SLC25A24 as a novel susceptibility gene for low fat mass in humans and mice. J Clin Endocrinol Metab. 2015;100:E655\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"1756_CR164","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7150\/ijms.8.599","volume":"8","author":"J Krammer","year":"2011","unstructured":"Krammer J, Digel M, Ehehalt F, Stremmel W, F\u00fcllekrug J, Ehehalt R. Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells. Int J Med Sci. 2011;8:599\u2013614.","journal-title":"Int J Med Sci"},{"key":"1756_CR165","doi-asserted-by":"publisher","first-page":"E384","DOI":"10.1152\/ajpendo.00226.2010","volume":"299","author":"A Falcon","year":"2010","unstructured":"Falcon A, Doege H, Fluitt A, Tsang B, Watson N, Kay MA, et al. FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am J Physiol Endocrinol Metab. 2010;299:E384\u201393.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1756_CR166","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1053\/j.gastro.2006.02.012","volume":"130","author":"B Hubbard","year":"2006","unstructured":"Hubbard B, Doege H, Punreddy S, Wu H, Huang X, Kaushik VK, et al. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology. 2006;130:1259\u201369.","journal-title":"Gastroenterology"},{"key":"1756_CR167","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1172\/JCI68807","volume":"123","author":"M Tamaki","year":"2013","unstructured":"Tamaki M, Fujitani Y, Hara A, Uchida T, Tamura Y, Takeno K, et al. The diabetes-susceptible gene SLC30A8\/ZnT8 regulates hepatic insulin clearance. J Clin Invest. 2013;123:4513\u201324.","journal-title":"J Clin Invest."},{"key":"1756_CR168","doi-asserted-by":"crossref","unstructured":"Fukunaka A, Fujitani Y. Role of zinc homeostasis in the pathogenesis of diabetes and obesity. Int J Mol Sci. 2018;19:476.","DOI":"10.3390\/ijms19020476"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01756-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01756-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01756-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:04:11Z","timestamp":1781877851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01756-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":168,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1756"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01756-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}